R&D News - Pharmaceutical Executive


R&D News
Corporate strategies and tactics for more effective drug development.

Pfizer Pulls Two Late-stage Drugs from Development

February 25, 2009

A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.

Latest Flu Season Sets Tamiflu Back but Doesn't Knock It Down

January 14, 2009

The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral.

Merck Submits Request to Market Gardasil to Men

January 7, 2009

Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck.

GSK Restructures Oncology Division

September 17, 2008

Glaxo's cancer departments will be consolidated into one big division encompassing discovery, research, and trials. The move is expected to cost some jobs, but GSK hopes it will strengthen synergy within its R&D unit.

Roche Touts Positive Data for Investigational Diabetes Drug

June 11, 2008

Swiss pharma giant Roche was abuzz at ADA, announcing that its new diabetes treatment is set for Phase III trials and commenting on future plans for failed CETP inhibitor dalcetrapib.

Risky Cholesterol Drug Proves Positive for Roche

April 2, 2008

While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse?

BioMS Medical Signs $500 Million Agreement with Lilly

January 9, 2008

Eli Lilly will help develop and market BioMS?s secondary progressive multiple sclerosis drug MBP8298, now in Phase III trials. If approved, the drug will be one of the only medications on the market to treat late-stage MS, a boon for both Lilly and BioMS.

BMS Cuts Bloated Manufacturing Arm to Bolster R&D

December 12, 2007

Bristol-Myers Squibb halves its manufacturing division and looks to unmet needs for innovation. Expect new oncology, diabetes, and cardiovascular drugs as well as a more streamlined approach to manufacturing.

Duke Partners with FDA to Modernize Clinical Trials

November 29, 2007

In an attempt to bring clinical trials into the 21st century, FDA and Duke launched a public–private partnership that will look at the current state of trials and determine what tools can be implemented to make trials safer and more efficient.


Click here